To further illustrate the use of PARP inhibitors, Table 2 summarizes key Phase III trials of olaparib in other BRCA/HRD-driven cancers—including HRD-positive breast cancer (OLYMPiAD trial) (Tutt et al., 2021), the POLO trial in pancreatic cancer (Gola et al., 2019; Kindler et al., 2022), and BRCA1/2-mutated prostate cancer (PROfound trial) (de Bono et al., 2020)—which demonstrated significant improvements in both progression-free survival and overall survival. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.